How Risky is MindMed Stock? (MMED / MMEDF Risk Assessment)

Today, we have a different episode for you..Usually we talk about all the things I am excited for when it comes to MindMed and MindMed stock, but today, we will visit the darker side by discussing how risky is the MindMed stock.
It is important for all psychedelic investors to grasp that MindMed is not a sure deal. Yes, I believe that long term it will succeed, but there are certain things that could go wrong.

We will cover the very real risks involved in investing in MindMed such as:
1. The possibility of MindMed’s medicines being inefficacious
– Whether of not MMED’s clinical trials succeed
2.MindMed’s incertain long term profitability
– Can the company scale production and training protocols?
3.MindMed Stock volatility
– MindMed’s market cap
– Future short interests

MindMed trades on the Canadian NEO Market as (MMED) and American OTC market as (MMEDF)

MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

https://mindmed.co/wp-content/uploads/2020/11/end-of-year-2019-discussion.pdf

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own

Psychedelic Spotlight

Interview with Matt Zemon, Co-Founder, Psychable

September 22, 2021June 2, 2024 Listen, Podcasts

In our conversation with Matt, we tackle a variety of extremely important and highly-relevant subject matters such as how technology can be utilized to enhance the community of psychedelic healing, conscious capitalism, corporate responsibility, and how companies like Psychable are willing to go out of their way to connect with investors who are motivated not only by profit, but a company’s ability to contribute to the greater good of humanity.

The Psychedelic Origin of Religion with Matthew Weintrub

April 6, 2023June 2, 2024 Listen, Podcasts

In this episode, we talk about the fascinating psychedelic brews from ancient history. They question if our account of Christian history is correct, and even suggest that psychedelics are in part responsible for the very concept of communing with God.

Why Are Psychedelic Stocks Falling? (MindMed, Atai, Cybin, FieldTrip, Compass Pathways)

October 14, 2021June 2, 2024 Listen, Videos

What’s up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), atai Life Sciences (atai: NASDAQ), Field Trip (FTRP: TSE) ( FTRP: NASDAQ), Cybin (CYBN: NYSE) and many more have experienced a decline in stock prices. So in this episode, we’ll be discussing the reasons behind this and whether we are ignoring some red flags.

Enjoy the episode!

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #FieldTrip #PsychedelicStocks

Interview with Zoe Helene, Founder of Cosmic Sister

October 22, 2021June 2, 2024 Listen, Podcasts

In our conversation, we discuss some of Zoe’s formative experiences in the creative arts which led her down the path of plant medicine advocacy, core feminist issues and how psychedelics play a role in furthering women’s movements, why an emphasis on equity and representation within the budding psychedelic industry is crucial and still has a long way to go, and so much more.

Curing Alcoholism with Ketamine Therapy? | Interview with Psychedelic Scientist Dr. Ben Sessa -Awakn

February 11, 2022June 2, 2024 Listen, Videos

In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.

In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.

From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.

Perhaps, psychedelics can treat mental health issues in general.

Perhaps, ketamine can be used to heal.

In the conversation, MDMA to treat addiction was also discussed.

Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.

With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.

From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.

#Psychedelics #Awakn #PsychedelicStocks

Spotlight Roundup-Another Psychedelic Company Lists On The Nasdaq

June 23, 2021June 2, 2024 Listen, Psychedelic Spotlight Videos

June 9, 2021- This week’s Psychedelic Business News top stories…